SMMT Latest Headlines

Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results

at www.tipranks.com (Thu, 3-Sep 11:48 AM)

Analysts Are Bullish on Top Healthcare Stocks: Summit Therapeutics (SMMT), Definitive Healthcare Corp (DH)

at www.tipranks.com (Thu, 3-Sep 9:50 AM)

Summit Therapeutics strengthened by positive ivonescimab survival results

at www.tipranks.com (Thu, 3-Sep 9:49 AM)

Summit Therapeutics: Ivonescimab’s Strengthened Survival Data Supports Buy Rating and Maintained $40 Price Target

at www.tipranks.com (Thu, 3-Sep 7:25 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Thu, 3-Sep 7:10 AM)

Analysts Offer Insights on Healthcare Companies: Newron Pharmaceuticals SpA (OtherNWPHF) and Summit Therapeutics (SMMT)

at www.tipranks.com (Thu, 3-Sep 6:20 AM)

Summit Therapeutics in focus as its lung cancer drug shows survival benefit

at seekingalpha.com (Wed, 2-Sep 6:09 PM)

Ten healthcare stocks leading in year-over-year CapEx growth

at seekingalpha.com (Wed, 2-Sep 8:02 AM)

Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season

at seekingalpha.com (Tue, 1-Sep 10:05 AM)

Dynatrace, Fluence, Five Below, Summit, BNS Trending With Analysts

at www.tipranks.com (Sat, 29-Aug 5:01 AM)

Ivonescimab Shows Significant Survival Benefit Over Durvalumab in Advanced Biliary Tract Cancer—What This Means for Summit Therapeutics’ Pipeline

Market Chameleon (Wed, 26-Aug 11:44 AM)

Ivonescimab Plus Chemotherapy Extends Progression-Free Survival in EGFR-Mutated NSCLC: Phase III HARMONi Study Results Published

Market Chameleon (Tue, 25-Aug 8:13 AM)

SMMT Highlights: Ivonescimab Approval in China Sets New Benchmark in Lung Cancer Treatment

Market Chameleon (Wed, 12-Aug 9:35 AM)

Ivonescimab’s Consistent Survival Benefit Highlights Summit Therapeutics’ Progress—PDUFA Date Set for November 2026

Market Chameleon (Fri, 24-Jul 7:06 AM)

Ivonescimab Plus Chemotherapy Achieves Consistent Survival Benefit for Western and Asian NSCLC Patients: Updated Phase III HARMONi Trial Data

Market Chameleon (Wed, 22-Jul 7:09 AM)

Summit Therapeutics Launches $500 Million Public Offering to Accelerate Ivonescimab Development

Market Chameleon (Wed, 10-Jun 7:05 AM)